NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
Clinical Trials
28 trialsNCT05896566 2026-02-24
PREcoopERA
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT00066690 2026-02-06
SOFT
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT05590793 2025-09-09
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Ipsen
Phase 3 Completed
NCT00667069 2025-06-05
Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
UNICANCER
Phase 3 Completed
NCT02278185 2025-05-11
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Phase 2 Completed
NCT01969578 2024-11-05
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT04727671 2023-10-24
Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.
Damascus University
Phase 4 Completed
NCT04727684 2023-10-24
Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI
Damascus University
Phase 4 Completed
NCT04071574 2023-05-09
CS-EOSP-ICSI
Lebanese University
Phase 1/2 Completed
NCT00104741 2021-02-21
Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
UNICANCER
Phase 3 Completed
NCT01753297 2020-12-09
PRIORITI
Ipsen
Phase 4 Completed
NCT04659551 2020-12-09
GIADA
Istituto Oncologico Veneto IRCCS
Phase 2 Completed
NCT01790126 2020-03-11
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 2 Completed
NCT01715129 2019-12-09
DKP 3M SC
Ipsen
Phase 3 Completed
NCT02005887 2019-05-29
TREND
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT01257425 2019-02-08
PAMIS
Ipsen
Phase 2 Completed
NCT01020448 2019-01-30
Triptocare
Ipsen
Phase 3 Completed
NCT01402336 2017-10-10
GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer
Seoul National University Hospital
Phase 3 Completed
NCT00659373 2016-07-25
Co-SOFT
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT01160315 2015-10-30
Erasme-POF
Erasme University Hospital
Phase 2/3 Completed
NCT02102646 2015-10-28
MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism
Herlev Hospital
Phase 4 Completed
NCT01656161 2015-09-15
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Debiopharm International SA
Phase 3 Completed
NCT01873378 2015-08-11
GnRH Agonist Pretreatment in Hysteroscopic Myomectomy
Azienda Ospedaliera S. Maria della Misericordia
Phase NA Completed
NCT00751790 2014-07-25
Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer
Debiopharm International SA
Phase 3 Completed
NCT01161563 2013-09-06
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
Watson Pharmaceuticals
Phase 4 Completed
NCT00311636 2013-06-26
Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT01764230 2013-01-09
OVARONKO
Masaryk University
Phase NA Completed